The Technical Analyst

NuCana PLC [NCNA]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

NuCana PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals

-2.37% GBP3.70

America/New_York / 19 apr 2024 @ 14:11

FIND ALL MARKETS FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo Live Signal Nasdaq Live Signal Crypto

NuCana PLC: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap:	7.75 mill
EPS:	-16.47
P/E:	-0.220
Earnings Date:	May 14, 2024
SharesOutstanding:	2.09 mill
Avg Daily Volume:	0.0719 mill

RATING 2024-04-19
B-
Sell

RATINGS
Rating CashFlow:	Neutral
Return On Equity:	Strong Sell
Return On Asset:	Strong Sell
DE:	Neutral
P/E:	Strong Sell
Price To Book:	Strong Buy

QUARTER GROWTHS
	3/22	4/22	1/23	2/23	3/23	4/23
Revenue	n/a	n/a	n/a	n/a	n/a	n/a
Gr.Profit	n/a	n/a	n/a	n/a	n/a	n/a
Ebit
Asset
Debt

PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.220 \| sector: PE -3.05

PE RATIO: COMPANY / INDUSTRY
-0.04x
Company: PE -0.220 \| industry: PE 5.88

DISCOUNTED CASH FLOW VALUE
GBP0.398 (-89.25%) GBP-3.30
Date: 2024-04-19

Expected Trading Range (DAY)
GBP 2.43 - 4.97 ( +/- 34.27%)
ATR Model: 14 days

Live Trading Signals (every 1 min)

Forecast 1: 14:20 - GBP3.68

Forecast 2: 15:10 - GBP3.61

Forecast 3: 15:50 - GBP3.68

SCORE
10.00
Buy

Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022

Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD

Volume Signals
Price	GBP3.70 (-2.37% )
Volume	0.0289 mill
Avg. Vol.	0.0719 mill
% of Avg. Vol	40.24 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for NuCana PLC

Last 12 Months

RSI

Last 10 Buy & Sell Signals For NCNA

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date	Signal	@	Closed	%

NCNA

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Last 10 Buy Signals

Date	Signal	@
ZM	Apr 19 - 14:44	$59.20
SETH2USD	Apr 19 - 14:41	3 053.95
QLYS	Apr 19 - 14:44	$162.58
FUTU	Apr 19 - 14:44	HKD54.67
CHRW	Apr 19 - 14:44	$71.13
CRSP	Apr 19 - 14:44	$54.41
CTXCUSD	Apr 19 - 14:43	$0.306
CRVUSD	Apr 19 - 14:43	$0.435
VRNS	Apr 19 - 14:41	$42.69
WBTCUSD	Apr 19 - 14:39	63 818

Latest Press Releases

2024-04-09 16:30:00 - Press Release

Nucana Presents Data At The Aacr 2024 Annual Meeting Highlighting The Ability Of Nuc-7738 To Profoundly Alter Tumor Biology In A Paired Biopsy Clinical Study

Nuc-7738 reprograms cancer cell lipid metabolism to make tumors less aggressive and promote cancer cell death

2024-03-27 16:30:00 - Press Release

Nucana Announces Plan To Implement Ads Ratio Change

Edinburgh, united kingdom, march 27, 2024 (globe newswire) -- nucana plc (nasdaq: ncna) announced plans to change the ratio of its american depository shares (“adss”) to its ordinary shares from one (1) ads, representing one (1) ordinary share, to one (1) ads representing twenty-five (25) ordinary shares (the "ads ratio"). the change in the ads ratio is expected to become effective on or about april 16, 2024 (the "effective date").

2024-03-20 16:01:00 - Press Release

Nucana Reports Fourth Quarter And Year-end 2023 Financial Results And Provides Business Update

Announced encouraging updates from nuc-3373 and nuc-7738 demonstrating promising efficacy and safety

2024-02-27 08:00:00 - Press Release

Nucana To Present At Td Cowen's 44th Annual Health Care Conference

Edinburgh, united kingdom, feb. 27, 2024 (globe newswire) -- nucana plc (nasdaq: ncna) announced today that hugh griffith, chief executive officer, and don munoz, chief financial officer, will present and host one-on-one meetings at td cowen's 44th annual health care conference.

2023-11-16 16:01:00 - Press Release

Nucana Reports Third Quarter 2023 Financial Results And Provides Business Update

Announced encouraging updates from nuc-3373 and nuc-7738 demonstrating promising efficacy and safety data

Latest News

2024-03-13 07:52:16 - InvestorPlace

Why Is NuCana (NCNA) Stock Up 102% Today?

NuCana (NASDAQ: NCNA ) stock is rising on Wednesday as the clinical-stage biopharmaceutical company's shares experience heavy trading this morning. That has more than 9.6 million shares of the company's stock changing hands as of this writing.

Full Story

2024-01-03 02:39:07 - Seeking Alpha

NuCana: Potential Turnaround In 2024 But Risky

NCNA is a beaten-down stock for numerous reasons, including failure of its prior lead candidate (Acelarin) in two phase 3 trials, as well as a limited cash runway. However, there are good reasons to believe that NCNA's current lead candidate, NUC-3373, will be successful. NUC-3373 aims to replace 5-fluorouracil (5FU) by overcoming its numerous limitations. Notably, 5FU is still used in a variety of malignancies. Importantly, 5FU-based chemotherapy regimens remain the cornerstone for treatment of colorectal cancer.

Full Story

2023-11-08 16:01:00 - GlobeNewsWire

NuCana to Present at the Jefferies London Healthcare Conference

EDINBURGH, United Kingdom, Nov. 08, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies London Healthcare Conference.

Full Story

2023-10-10 08:46:20 - InvestorPlace

Why Is NuCana (NCNA) Stock Down Today?

NuCana (NASDAQ: NCNA ) stock is sliding lower on Tuesday as the clinical-stage biopharmaceutical company prepares for a presentation this week. NuCana is set to attend the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 in Boston, Mass.

Full Story

2023-09-28 11:17:30 - Zacks Investment Research

Bears are Losing Control Over NuCana PLC Sponsored ADR (NCNA), Here's Why It's a 'Buy' Now

NuCana PLC Sponsored ADR (NCNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Full Story

2023-06-01 08:00:00 - GlobeNewsWire

NuCana to Present at the Jefferies Healthcare Conference

EDINBURGH, United Kingdom, June 01, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Healthcare Conference.

Full Story

2023-03-27 09:21:43 - InvestorPlace

Why Is NuCana (NCNA) Stock Down 36% Today?

NuCana (NASDAQ: NCNA ) stock is sliding lower on Monday after the company got an unfortunate update from the Technical Board of Appeal (TBA) of the European Patent Office (EPO). The bad news for investors in NCNA stock is the TBA has determined that the company's European Patent 2955190 isn't valid.

Full Story

2023-02-28 08:00:00 - GlobeNewsWire

NuCana to Participate in Two Upcoming Investor Conferences

EDINBURGH, United Kingdom, Feb. 28, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in two upcoming investor conferences.

Full Story

2023-01-08 04:30:40 - Seeking Alpha

NuCana: Pipeline And Major Gilead Litigation Progressing Nicely

NuCana's market cap is not reflecting the potential of two other drug candidates NUC-3373 and NUC-7738, currently in Phase 2 trials. The UK and EU proceedings against Gilead for alleged years-long infringement of an EU patent have important hearing dates lined up in January and March 2023.

Full Story

2022-11-21 13:32:28 - Zacks Investment Research

NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?

NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Full Story

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.